[Therapeutic action of radioprotector indometofen]

The experiments on mice and dogs have shown the effectiveness of indomethofene administration after total acute radiation exposure. Introduction of indomethofene at doses of 15 and 30 mg/kg during time from 30 min to 3 days after irradiation resulted in reliable increase of mice survivability, 40-60% on average. Mice survival rate after single peroral introduction of indomethofene radioprotective doses was comparable with that resulting from referencing preparation estrofeme, which is estradiol oral dosage from (under the assumption that in contrast to indometafene estrofeme was introduced repeatedly every other day from 3 till 21 day after irradiation). Therapeutic action of indomethofene was confirmed in the experiments on dogs. After radiation exposure at a dose which caused the death of all dogs of control group, survival rate of experimental animals which received single oral dosage form of indomethofene at radioprotective dose in 1 and 3 days after irradiation was 40%. This study showed that indomethofene--long-acting radioprotector--is effective as therapeutic agent for acute radiation damage treatment.